---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-11T08:50:25.449398'
end_time: '2026-02-11T08:55:44.379720'
duration_seconds: 318.93
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: ACAD9
  gene_symbol: ACAD9
  uniprot_accession: Q9H845
  protein_description: 'RecName: Full=Complex I assembly factor ACAD9, mitochondrial
    {ECO:0000303|PubMed:24158852}; AltName: Full=Acyl-CoA dehydrogenase family member
    9 {ECO:0000303|PubMed:12359260}; Short=ACAD-9 {ECO:0000303|PubMed:12359260}; EC=1.3.8.7
    {ECO:0000269|PubMed:16020546}; EC=1.3.8.8 {ECO:0000269|PubMed:12359260, ECO:0000269|PubMed:16020546,
    ECO:0000269|PubMed:21237683, ECO:0000269|PubMed:24158852}; Flags: Precursor;'
  gene_info: Name=ACAD9 {ECO:0000312|HGNC:HGNC:21497};
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the acyl-CoA dehydrogenase family.
  protein_domains: ACAD9/ACADV-like_C. (IPR049448); Acyl-CoA_DH_CS. (IPR006089); Acyl-CoA_Oxase/DH_mid-dom.
    (IPR006091); Acyl-CoA_Oxase/DH_mid-dom_sf. (IPR046373); AcylCo_DH-like_C. (IPR036250)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 20
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9H845
- **Protein Description:** RecName: Full=Complex I assembly factor ACAD9, mitochondrial {ECO:0000303|PubMed:24158852}; AltName: Full=Acyl-CoA dehydrogenase family member 9 {ECO:0000303|PubMed:12359260}; Short=ACAD-9 {ECO:0000303|PubMed:12359260}; EC=1.3.8.7 {ECO:0000269|PubMed:16020546}; EC=1.3.8.8 {ECO:0000269|PubMed:12359260, ECO:0000269|PubMed:16020546, ECO:0000269|PubMed:21237683, ECO:0000269|PubMed:24158852}; Flags: Precursor;
- **Gene Information:** Name=ACAD9 {ECO:0000312|HGNC:HGNC:21497};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the acyl-CoA dehydrogenase family.
- **Key Domains:** ACAD9/ACADV-like_C. (IPR049448); Acyl-CoA_DH_CS. (IPR006089); Acyl-CoA_Oxase/DH_mid-dom. (IPR006091); Acyl-CoA_Oxase/DH_mid-dom_sf. (IPR046373); AcylCo_DH-like_C. (IPR036250)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "ACAD9" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'ACAD9' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **ACAD9** (gene ID: ACAD9, UniProt: Q9H845) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9H845
- **Protein Description:** RecName: Full=Complex I assembly factor ACAD9, mitochondrial {ECO:0000303|PubMed:24158852}; AltName: Full=Acyl-CoA dehydrogenase family member 9 {ECO:0000303|PubMed:12359260}; Short=ACAD-9 {ECO:0000303|PubMed:12359260}; EC=1.3.8.7 {ECO:0000269|PubMed:16020546}; EC=1.3.8.8 {ECO:0000269|PubMed:12359260, ECO:0000269|PubMed:16020546, ECO:0000269|PubMed:21237683, ECO:0000269|PubMed:24158852}; Flags: Precursor;
- **Gene Information:** Name=ACAD9 {ECO:0000312|HGNC:HGNC:21497};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the acyl-CoA dehydrogenase family.
- **Key Domains:** ACAD9/ACADV-like_C. (IPR049448); Acyl-CoA_DH_CS. (IPR006089); Acyl-CoA_Oxase/DH_mid-dom. (IPR006091); Acyl-CoA_Oxase/DH_mid-dom_sf. (IPR046373); AcylCo_DH-like_C. (IPR036250)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "ACAD9" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'ACAD9' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **ACAD9** (gene ID: ACAD9, UniProt: Q9H845) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research plan and verification steps
- We verified the target: ACAD9 (HGNC:21497), UniProt Q9H845, a human mitochondrial acyl‑CoA dehydrogenase–family protein that functions as an essential Complex I (CI) assembly factor. Literature consistently identifies ACAD9 as a FAD‑binding homodimer paralogous to VLCAD that participates in CI biogenesis via the MCIA complex, confirming alignment with the UniProt description, domains, and family membership. No conflicting gene symbol usage was encountered in other organisms within the cited literature (all human-focused) (xia2021molecularmechanismof pages 1-2, xia2021molecularmechanismof pages 14-16, xia2021molecularmechanismof pages 2-4, mcgregor2023theassemblyof pages 1-2, nouws2013humanmitochondrialcomplex pages 70-73).

Comprehensive research report
1) Key concepts and definitions (current understanding)
- Identity and dual function: ACAD9 is a FAD‑dependent acyl‑CoA dehydrogenase paralog that also serves as an essential assembly factor for mitochondrial Complex I (CI). As an enzyme, ACAD9 catalyzes the α,β‑dehydrogenation step of long‑chain fatty acyl‑CoA in fatty‑acid β‑oxidation (FAO). As an assembly factor, ACAD9 is a core member of the Mitochondrial Complex I Assembly (MCIA) complex, partnering with ECSIT and NDUFAF1 to build the ND2 membrane‑arm module of CI (functions are mutually exclusive; see below) (xia2021molecularmechanismof pages 1-2, xia2021molecularmechanismof pages 14-16, xia2021molecularmechanismof pages 2-4, mcgregor2023theassemblyof pages 1-2).
- Primary role in vivo: Multiple genetic and cell‑biological studies indicate that ACAD9’s predominant physiological role is in CI biogenesis, with knockdown or mutation producing isolated CI deficiency and accumulation of defined assembly intermediates (nouws2013humanmitochondrialcomplex pages 70-73, schiff2015complexiassembly pages 1-2).

2) Molecular function and enzymatic activity (substrate specificity) versus assembly role
- Enzymatic activity: Purified human ACAD9 forms a FAD‑containing homodimer with measurable dehydrogenation activity toward long‑chain acyl‑CoA substrates; its catalytic rate is lower than VLCAD (~20% of VLCAD under comparable conditions). FAD binding stabilizes the ACAD9 dimer; the catalytic glutamate (E426) is essential for activity. ACAD9 exhibits sub‑stoichiometric FAD occupancy in vitro (~70%), and activity can be increased by adding FAD, reflecting relatively weak FAD binding in the apo state (xia2021molecularmechanismof pages 2-4, xia2021molecularmechanismof pages 13-14, xia2021molecularmechanismof pages 1-2).
- Assembly role via MCIA: ACAD9 forms the core MCIA ternary complex by binding ECSIT (ACAD9 N‑terminal domain to ECSIT C‑terminal domain) and NDUFAF1 (to ECSIT N‑terminal domain). This ternary complex is stable and required for assembly of ND2‑module intermediates of CI; loss of MCIA components causes specific CI assembly failure (xia2021molecularmechanismof pages 1-2, xia2021molecularmechanismof pages 14-16).
- Functional exclusivity and switching: Binding of ECSIT to ACAD9 triggers “deflavination” (loss of the FAD cofactor) and abrogates dehydrogenase activity, thereby switching ACAD9 from an FAO enzyme to a CI assembly factor. ECSIT and ETF (electron transfer flavoprotein) compete for overlapping sites on ACAD9’s N‑terminal region near FAD, mechanistically enforcing mutual exclusivity between FAO (ETF‑bound, FAD‑loaded) and assembly (ECSIT‑bound, deflavinated) states (xia2021molecularmechanismof pages 1-2, xia2021molecularmechanismof pages 14-16, xia2021molecularmechanismof pages 13-14, giachin2021assemblyofthe pages 3-4).

3) Subcellular localization, interacting partners, and structural mechanisms
- Localization: ACAD9 is a mitochondrial matrix‑facing homodimer associated with the inner membrane where CI is assembled (nouws2013humanmitochondrialcomplex pages 70-73).
- Interacting partners: Core MCIA partners include ECSIT and NDUFAF1; the MCIA functional module cooperates with TMEM126B/TMEM186 in ND2‑arm assembly. ETF interacts with ACAD9 in its enzymatic (FAO) state but is excluded by ECSIT during assembly (xia2021molecularmechanismof pages 2-4, xia2021molecularmechanismof pages 1-2, xia2021molecularmechanismof pages 14-16, xia2021molecularmechanismof pages 13-14).
- Structural mechanism (deflavination): High‑resolution structural and biophysical work demonstrates that a C‑terminal ECSIT fragment binds ACAD9 and induces a conformational change in the FAD‑binding loop, causing FAD release (“deflavination”). Key interfacial residues include a salt bridge (ECSIT Glu323–ACAD9 Lys228) and a hydrogen bond (ECSIT Trp324–ACAD9 Ser191). ECSIT phosphorylation reduces ACAD9 binding; exposure of neuronal cells to amyloid‑β oligomers lowers ECSIT phosphorylation and promotes ECSIT–ACAD9 association, linking MCIA regulation to neurodegenerative stress (mcgregor2023theassemblyof pages 1-2, giachin2021assemblyofthe pages 3-4).

4) Disease associations and phenotypes
- Isolated Complex I deficiency: ACAD9 mutations produce isolated CI deficiency with phenotypes ranging from severe neonatal disease (metabolic acidosis, Leigh syndrome, hypertrophic cardiomyopathy) to later‑onset myopathy and multisystem involvement. Early multicenter cohorts demonstrated that ACAD9 loss compromises CI assembly and activity in patient cells and tissues (schiff2015complexiassembly pages 1-2, nouws2013humanmitochondrialcomplex pages 70-73).
- Clinical spectrum and severity: A large compiled cohort of 70 ACAD9‑deficient patients reported high early mortality (>50% within the first year) among severe infantile cases; individuals with onset after 1 year of age had markedly better survival (>80%), often with riboflavin responsiveness (see below) (murgia2023newinsightsinto pages 9-11).
- Contribution of FAO impairment: Functional analyses of 16 ACAD9 variants from 24 patients support that both CI assembly failure and partial loss of ACAD enzymatic function correlate with disease severity; tissues with high ACAD9 expression (e.g., liver, neurons) may be more sensitive to its FAO role, complementing its obligatory assembly function (schiff2015complexiassembly pages 1-2).

5) Riboflavin (vitamin B2) responsiveness and therapeutic rationale
- Mechanistic rationale: As a FAD precursor, riboflavin may act as a chemical chaperone by improving FAD loading, folding, and stability of mutant ACAD9, partially restoring function. In vitro, excess FAD can restore dehydrogenase activity to ACAD9/ECSIT complexes, consistent with this model (xia2021molecularmechanismof pages 13-14).
- Clinical evidence: Cohort‑level data indicate that later‑onset ACAD9 deficiency often responds to riboflavin with improved outcomes, while severe neonatal cases show limited benefit. Individual patient fibroblast studies document increased CI activity (e.g., 1.7–2.1×) after riboflavin exposure, though not all genotypes respond (e.g., variants near the FAD pocket showed poor response in one case), underscoring genotype‑specific effects and the need for clinical monitoring (murgia2023newinsightsinto pages 9-11, nouws2013humanmitochondrialcomplex pages 117-118).

6) Recent developments (prioritized 2023–2024)
- Structural basis of the switch to assembly: Nature Communications (2023) defined the ECSIT–ACAD9 interface that enforces deflavination and the functional switch to CI assembly; it also linked ECSIT phosphorylation dynamics to amyloid‑β exposure in neurons, suggesting stress‑regulated control of MCIA (mcgregor2023theassemblyof pages 1-2).
- Ongoing refinement of MCIA mechanisms: Contemporary structural/biophysical paradigms from 2021–2023 consolidate that MCIA relies on ECSIT as a bridging hub that binds ACAD9 C‑terminally and NDUFAF1 N‑terminally, rendering a stable complex that coordinates formation of ND2‑module intermediates and underscores the biochemical exclusivity between FAO and assembly states (xia2021molecularmechanismof pages 1-2, xia2021molecularmechanismof pages 14-16, giachin2021assemblyofthe pages 3-4, mcgregor2023theassemblyof pages 1-2).
- Translational perspective: A 2023 nutrition‑genomics review synthesizes cohort data on riboflavin‑responsive flavoprotein disorders including ACAD9, highlighting survival statistics, genotypic nuances, and proposing personalized riboflavin therapy frameworks for late‑onset cases (murgia2023newinsightsinto pages 9-11).

7) Current applications and real‑world implementations
- Diagnostics: Next‑generation sequencing for suspected mitochondrial disease frequently identifies ACAD9 variants; functional confirmation includes BN‑PAGE/enzymology for CI deficiency and, when feasible, FAO flux testing in tissues with higher ACAD9 expression. The dual role cautions that skin fibroblasts (low ACAD9) may under‑detect FAO defects, whereas HEK293 and high‑expression tissues better reveal enzymatic contributions (schiff2015complexiassembly pages 1-2, nouws2013humanmitochondrialcomplex pages 70-73).
- Therapeutic approaches: Riboflavin supplementation is commonly attempted given its safety and potential benefit; responses should be tracked clinically and biochemically (e.g., lactate, exercise tolerance, CI activity), recognizing variability by genotype and age of onset (murgia2023newinsightsinto pages 9-11, nouws2013humanmitochondrialcomplex pages 117-118).

8) Expert opinions and authoritative analyses
- Mechanistic consensus: ACAD9 is now broadly regarded as a moonlighting protein whose enzymatic FAO capacity is vestigial relative to VLCAD yet physiologically relevant in select tissues; its dominant essential role is as a CI assembly factor within MCIA. Deflavination triggered by ECSIT is the key structural‑biochemical switch between these roles (xia2021molecularmechanismof pages 1-2, xia2021molecularmechanismof pages 14-16, giachin2021assemblyofthe pages 3-4, mcgregor2023theassemblyof pages 1-2, nouws2013humanmitochondrialcomplex pages 70-73).
- Clinical consensus: ACAD9 deficiency is a leading cause of nuclear‑encoded isolated CI deficiency, with cardiomyopathy common; riboflavin responsiveness is documented in many late‑onset cases though not uniform, and cohort data motivate genotype‑informed, monitored trials (murgia2023newinsightsinto pages 9-11, nouws2013humanmitochondrialcomplex pages 117-118, schiff2015complexiassembly pages 1-2).

9) Quantitative statistics and selected data
- Enzyme biochemistry: Purified ACAD9 dimer shows ~70% FAD occupancy; catalytic activity increases with exogenous FAD (half‑maximal stimulation ~0.75 mM FAD). Mutating the catalytic E426 abolishes activity, confirming canonical ACAD chemistry (xia2021molecularmechanismof pages 2-4).
- Assembly biochemistry: ECSIT binding to ACAD9 causes loss of FAD and dehydrogenase activity; ETF and ECSIT compete for overlapping binding surfaces near the N‑terminal/FAD region (xia2021molecularmechanismof pages 1-2, xia2021molecularmechanismof pages 14-16).
- Clinical cohorts: In a compiled 70‑patient ACAD9 cohort, >50% infant mortality within the first year in severe early‑onset disease; survival >80% in those with onset after 1 year, many of whom received riboflavin (murgia2023newinsightsinto pages 9-11).
- Functional variant testing: Across 16 ACAD9 variants from 24 patients, residual enzymatic activity inversely correlated with clinical severity, supporting a contributory FAO component in disease alongside the required CI assembly function (schiff2015complexiassembly pages 1-2).

10) Pathway placement and cellular site of action
- ACAD9’s assembly function operates at the matrix side of the inner mitochondrial membrane within the MCIA complex to guide ND2‑module formation and integration into CI. Its FAO enzyme function, when engaged, participates in mitochondrial long‑chain fatty‑acid β‑oxidation, transferring electrons to ETF; these two states are structurally incompatible due to ECSIT‑mediated deflavination and ETF competition (nouws2013humanmitochondrialcomplex pages 70-73, xia2021molecularmechanismof pages 1-2, xia2021molecularmechanismof pages 14-16).

References with URLs and publication dates
- McGregor L, et al. The assembly of the Mitochondrial Complex I Assembly complex uncovers a redox pathway coordination. Nature Communications. 2023-12. https://doi.org/10.1038/s41467-023-43865-0 (mcgregor2023theassemblyof pages 1-2)
- Xia C, et al. Molecular mechanism of interactions between ACAD9 and binding partners in mitochondrial respiratory complex I assembly. iScience. 2021-10. https://doi.org/10.1016/j.isci.2021.103153 (xia2021molecularmechanismof pages 1-2, xia2021molecularmechanismof pages 14-16, xia2021molecularmechanismof pages 13-14, xia2021molecularmechanismof pages 2-4)
- Giachin G, et al. Assembly of The Mitochondrial Complex I Assembly Complex Suggests a Regulatory Role for Deflavination. Angew Chem Int Ed. 2021-01. https://doi.org/10.1002/anie.202011548 (giachin2021assemblyofthe pages 3-4)
- Nouws J. Human mitochondrial complex I biogenesis: connections between mitochondrial translation, fatty acid oxidation and complex I assembly. Thesis/monograph. 2013. (contains experimental summaries cited above) (nouws2013humanmitochondrialcomplex pages 70-73, nouws2013humanmitochondrialcomplex pages 117-118)
- Schiff M, et al. Complex I assembly function and fatty acid oxidation enzyme activity of ACAD9 both contribute to disease severity in ACAD9 deficiency. Hum Mol Genet. 2015-06. https://doi.org/10.1093/hmg/ddv074 (schiff2015complexiassembly pages 1-2)
- Murgia C, Dehlia A, Guthridge MA. New insights into the nutritional genomics of adult‑onset riboflavin‑responsive diseases. Nutr Metab (Lond). 2023-10. https://doi.org/10.1186/s12986-023-00764-x (murgia2023newinsightsinto pages 9-11)

Methodological notes and limitations
- While 2023–2024 sources substantially refine ACAD9’s structural switching and regulatory context (deflavination; ECSIT phosphorylation), large controlled treatment trials for riboflavin in ACAD9 deficiency remain limited. Reported cohort statistics come from compiled retrospective cohorts and reviews; genotype‑specific responsiveness should be interpreted cautiously and validated case‑by‑case (mcgregor2023theassemblyof pages 1-2, murgia2023newinsightsinto pages 9-11, nouws2013humanmitochondrialcomplex pages 117-118).

References

1. (xia2021molecularmechanismof pages 1-2): Chuanwu Xia, Baoying Lou, Zhuji Fu, Al-Walid Mohsen, Anna L. Shen, Jerry Vockley, and Jung-Ja P. Kim. Molecular mechanism of interactions between acad9 and binding partners in mitochondrial respiratory complex i assembly. iScience, 24:103153, Oct 2021. URL: https://doi.org/10.1016/j.isci.2021.103153, doi:10.1016/j.isci.2021.103153. This article has 25 citations and is from a peer-reviewed journal.

2. (xia2021molecularmechanismof pages 14-16): Chuanwu Xia, Baoying Lou, Zhuji Fu, Al-Walid Mohsen, Anna L. Shen, Jerry Vockley, and Jung-Ja P. Kim. Molecular mechanism of interactions between acad9 and binding partners in mitochondrial respiratory complex i assembly. iScience, 24:103153, Oct 2021. URL: https://doi.org/10.1016/j.isci.2021.103153, doi:10.1016/j.isci.2021.103153. This article has 25 citations and is from a peer-reviewed journal.

3. (xia2021molecularmechanismof pages 2-4): Chuanwu Xia, Baoying Lou, Zhuji Fu, Al-Walid Mohsen, Anna L. Shen, Jerry Vockley, and Jung-Ja P. Kim. Molecular mechanism of interactions between acad9 and binding partners in mitochondrial respiratory complex i assembly. iScience, 24:103153, Oct 2021. URL: https://doi.org/10.1016/j.isci.2021.103153, doi:10.1016/j.isci.2021.103153. This article has 25 citations and is from a peer-reviewed journal.

4. (mcgregor2023theassemblyof pages 1-2): Lindsay McGregor, Samira Acajjaoui, Ambroise Desfosses, Melissa Saïdi, Maria Bacia-Verloop, Jennifer J. Schwarz, Pauline Juyoux, Jill von Velsen, Matthew W. Bowler, Andrew A. McCarthy, Eaazhisai Kandiah, Irina Gutsche, and Montserrat Soler-Lopez. The assembly of the mitochondrial complex i assembly complex uncovers a redox pathway coordination. Nature Communications, Dec 2023. URL: https://doi.org/10.1038/s41467-023-43865-0, doi:10.1038/s41467-023-43865-0. This article has 31 citations and is from a highest quality peer-reviewed journal.

5. (nouws2013humanmitochondrialcomplex pages 70-73): J Nouws. Human mitochondrial complex i biogenesis. connections between mitochondrial translation, fatty acid oxidation and complex i assembly. Unknown journal, 2013.

6. (schiff2015complexiassembly pages 1-2): Manuel Schiff, Birgit Haberberger, Chuanwu Xia, Al-Walid Mohsen, Eric S Goetzman, Yudong Wang, Radha Uppala, Yuxun Zhang, Anuradha Karunanidhi, Dolly Prabhu, Hana Alharbi, Edward V Prochownik, Tobias Haack, Johannes Häberle, Arnold Munnich, Agnes Rötig, Robert W Taylor, Robert D Nicholls, Jung-Ja Kim, Holger Prokisch, and Jerry Vockley. Complex i assembly function and fatty acid oxidation enzyme activity of acad9 both contribute to disease severity in acad9 deficiency. Human molecular genetics, 24 11:3238-47, Jun 2015. URL: https://doi.org/10.1093/hmg/ddv074, doi:10.1093/hmg/ddv074. This article has 78 citations and is from a domain leading peer-reviewed journal.

7. (xia2021molecularmechanismof pages 13-14): Chuanwu Xia, Baoying Lou, Zhuji Fu, Al-Walid Mohsen, Anna L. Shen, Jerry Vockley, and Jung-Ja P. Kim. Molecular mechanism of interactions between acad9 and binding partners in mitochondrial respiratory complex i assembly. iScience, 24:103153, Oct 2021. URL: https://doi.org/10.1016/j.isci.2021.103153, doi:10.1016/j.isci.2021.103153. This article has 25 citations and is from a peer-reviewed journal.

8. (giachin2021assemblyofthe pages 3-4): Gabriele Giachin, Matthew Jessop, Romain Bouverot, Samira Acajjaoui, Melissa Saïdi, Anaïs Chretien, Maria Bacia‐Verloop, Luca Signor, Philippe J. Mas, Adrien Favier, Eve Borel Meneroud, Michael Hons, Darren J. Hart, Eaazhisai Kandiah, Elisabetta Boeri Erba, Alain Buisson, Gordon Leonard, Irina Gutsche, and Montserrat Soler‐Lopez. Assembly of the mitochondrial complex i assembly complex suggests a regulatory role for deflavination. Angewandte Chemie International Edition, 60:4689-4697, Jan 2021. URL: https://doi.org/10.1002/anie.202011548, doi:10.1002/anie.202011548. This article has 28 citations.

9. (murgia2023newinsightsinto pages 9-11): Chiara Murgia, Ankush Dehlia, and Mark A. Guthridge. New insights into the nutritional genomics of adult-onset riboflavin-responsive diseases. Nutrition & Metabolism, Oct 2023. URL: https://doi.org/10.1186/s12986-023-00764-x, doi:10.1186/s12986-023-00764-x. This article has 17 citations and is from a peer-reviewed journal.

10. (nouws2013humanmitochondrialcomplex pages 117-118): J Nouws. Human mitochondrial complex i biogenesis. connections between mitochondrial translation, fatty acid oxidation and complex i assembly. Unknown journal, 2013.

## Citations

1. nouws2013humanmitochondrialcomplex pages 70-73
2. murgia2023newinsightsinto pages 9-11
3. schiff2015complexiassembly pages 1-2
4. xia2021molecularmechanismof pages 13-14
5. mcgregor2023theassemblyof pages 1-2
6. xia2021molecularmechanismof pages 2-4
7. giachin2021assemblyofthe pages 3-4
8. xia2021molecularmechanismof pages 1-2
9. xia2021molecularmechanismof pages 14-16
10. nouws2013humanmitochondrialcomplex pages 117-118
11. https://doi.org/10.1038/s41467-023-43865-0
12. https://doi.org/10.1016/j.isci.2021.103153
13. https://doi.org/10.1002/anie.202011548
14. https://doi.org/10.1093/hmg/ddv074
15. https://doi.org/10.1186/s12986-023-00764-x
16. https://doi.org/10.1016/j.isci.2021.103153,
17. https://doi.org/10.1038/s41467-023-43865-0,
18. https://doi.org/10.1093/hmg/ddv074,
19. https://doi.org/10.1002/anie.202011548,
20. https://doi.org/10.1186/s12986-023-00764-x,